Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.
Twitter handle: @jeffmason1
Nabriva Therapeutics Plc's antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer's shares down 13 percent on Monday.
U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent.
Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson & Johnson on Tuesday, setting it up to compete against more established brands.
Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.
Valeant Pharmaceuticals International Inc said on Tuesday it will change its name to Bausch Health Companies Inc as it seeks to distance itself from a series of scandals and accounting issues under the drug company's previous management.
Elliott Management has proposed an all cash offer of $160 per share for Athenahealth Inc that would value the healthcare software maker at about $6.9 billion including debt, the hedge fund said in a letter Monday.
Cardinal Health Inc's quarterly profit missed analysts' expectations as inventory and cost issues hurt its Cordis medical device unit, and the U.S. drug distributor said it saw prices of generic drugs fall more than expected.
Allergan Plc's chief executive on Monday said he was opposed to fundamental changes to the drug company's business strategy, even as its board considers drastic moves like splitting the company, selling off assets or doing deals to turn around a steep drop in its share price.
Vertex Pharmaceuticals Inc topped analysts' forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments.
Edwards Lifesciences Corp's first-quarter sales for transcatheter heart valves missed Wall Street targets on Tuesday, as the medical device maker lost market share in Europe to its rival, Medtronic Plc .
- Gold: PRECIOUS-Gold eases as higher dollar offsets concern over U.S.-China trade talks
- Oil Report: CORRECTED-WRAPUP 2-Malaysia's Mahathir widens graft crackdown, seeks to cut national debt
- British Pound Report: UPDATE 2-Sterling tumbles after weak UK inflation
- US Dollar Report: FOREX-Euro plunges as risk aversion, Italy concerns weigh